Abbott Laboratories (ABT) scored on five pillars from its reported financial statements, and ranked against 212 Healthcare companies.
Abbott Laboratories (ABT) scores 5.6 out of 10 as of , computed from its reported financial statements. That reads as solid quality. The reading rests on solvency, and growth is what holds it back.
Data provided by Twelve Data. Scores are computed by Lemma Analysis from reported financials.
Abbott Laboratories’s returns on capital beat their cost in almost every measured year, by a clear margin: 5 of 5 indicators passed.
Quantitative signs of a moat, read from the filed statements. This is not a judgement of where it comes from (brand, network effects, switching costs). How Lemma measures a moat →
The Quality Score for ABT stands at 5.6 out of 10 as of October 19, 2026, which puts Abbott Laboratories in the solid quality band. This band covers companies that do several things well but not everything, so the pillar detail below matters more than the headline. It rolls Abbott Laboratories’s profitability, solvency, growth, efficiency and predictability into one number, each judged against the norms of its sector.
Set against 212 Healthcare companies, Abbott Laboratories lands at the 67th percentile, in the upper half of the group, short of the top quarter. For reference, the middle of the group scores 4.4 and a company needs 6.0 to reach its top quarter, which leaves Abbott Laboratories above the median.
Profitability scores 4.9 out of 10, which reads as average. The median across 210 Healthcare companies is 2.7, so Abbott Laboratories is well above its peers on this pillar and ranks at the 71st percentile. Profitability in the middle of the range is neither a moat nor a warning: margins and returns look like those of an ordinary business in this line of work.
Solvency scores 8.4 out of 10, which reads as strong. The median across 150 Healthcare companies is 6.5, so Abbott Laboratories is well above its peers on this pillar and ranks at the 71st percentile. Balance sheet strength like this rarely makes headlines, but it is what lets a company keep investing when credit gets expensive.
Abbott Laboratories’s growth score is 2.6 out of 10 (weak). Against a median of 4.9 among 107 Healthcare companies, that is well below the group and the 25th percentile. When growth is this low the question is whether it is a pause or a trend, and the history behind the filings is the place to look.
Efficiency scores 6.4 out of 10, which reads as average. The median across 200 Healthcare companies is 6.0, so Abbott Laboratories is in line with its peers on this pillar and ranks at the 55th percentile. Middling efficiency is unremarkable on its own, though improvements here tend to show up in free cash flow first.
On predictability, Abbott Laboratories scores 6.0, an average reading. Its peers have a median of 3.4 across 207 Healthcare companies, which places it well above them, at the 82nd percentile. Consistency near the median is typical, and it is worth checking whether the swings came from the business itself or from one-off items.
The gap between Abbott Laboratories’s best and worst pillar is wide: solvency at 8.4 against growth at 2.6, 5.8 points apart. An average of two readings this different deserves a closer look than the headline number. Leading with solvency is a defensive strength: it protects the business more than it grows it. Slow growth limits how fast the business can compound, even when everything else is in order.
Closing the gap on growth would do the most for the overall. At the median of Healthcare companies, 4.9, Abbott Laboratories would score about 6.1 instead of 5.6. The weights add up to 100 points (profitability 25, solvency 20, growth 20, efficiency 15, predictability 20), and Abbott Laboratories has a reading on every pillar.
For a fair comparison, start with companies of a similar size: the Healthcare companies below are nearest to Abbott Laboratories by market value, each scored on the same pillars.
How much profit the company generates from its capital and sales.
The company’s ability to service debt and meet its obligations.
How fast revenue, earnings and cash flow are compounding.
How well assets and earnings convert into cash and output.
How stable and consistent results have been over time.
Each metric is scored from 0 to 10 against sector-aware benchmarks, where higher is better. Metrics roll up into five pillars, and the pillars combine into the overall score using the weights shown. Sector-sensitive metrics are judged relative to peers in the same sector.
This score is a systematic, backward-looking read of reported fundamentals. It does not judge valuation, management quality, competitive moat, or future prospects, and can be distorted by one-off items or unusual accounting. Treat it as a starting point, not a recommendation.
Educational only. Not investment advice.
On this reading Abbott Laboratories scores 5.6 out of 10, which reads as solid quality. Its strongest pillar is solvency, its weakest is growth. Quality is not the same as a good investment: the score says nothing about the price you would pay.
Abbott Laboratories ranks at the 67th percentile of the 212 Healthcare companies Lemma publishes a score for. The median there is 4.4 and the top quarter starts at 6.0, against Abbott Laboratories’s 5.6.
Five pillars, each scored from 0 to 10 against sector-aware benchmarks and then weighted into one overall reading: profitability, solvency, growth, efficiency and predictability. Everything comes from reported financials, and nothing comes from price, sentiment or forecasts.
This page last changed on October 19, 2026. The score moves with the financial statements, so the page changes when a new filing moves the reading rather than on a schedule. Live figures for ABT are in the app.
No. Quality and valuation are separate questions, and a good business at the wrong price is still a bad purchase. Score the business here, then price it with a DCF you control.
Inside Lemma Analysis the same five pillars run on every company we cover, with the metrics behind each one, current fundamentals, a DCF you control and a watchlist that tells you when the price catches up.
Free to start · No credit card